Evidence-Based Practice: One Size Does Not Fit All
Author weighs evidence-based medicine vs experience and common sense when treating a patient with Alzheimer disease and cold symptoms.
Author weighs evidence-based medicine vs experience and common sense when treating a patient with Alzheimer disease and cold symptoms.
In an expert roundtable, clinicians discuss the risks, benefits, and anticipated real-world usage of lecanemab following US FDA approval.
Individuals with a higher adherence to a Mediterranean diet had up to 23 percent lower risk for dementia, regardless of genetic risk.
A team of investigators evaluated numerous factors associated with the management of pain among residents of nursing homes with dementia.
Timothy S. Chang, MD, PhD and Lisa L. Barnes, PhD, discuss health disparities in Alzheimer disease and related dementias and how to improve clinical outcomes for patients from underrepresented groups.
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
Approval of the Alzheimer medication lecanemab comes after controversial approval in 2021 of aducanumab, which met with criticism over concerns about that drug’s effectiveness, safety, pricing
Research findings support the use of vitamin D supplementation to help slow cognitive decline in Alzheimer dementia and reduce Parkinson disease symptom severity.
Cardiovascular and genetic risk factors may predict decreased brain volume in Alzheimer disease-specific brain regions in high-risk postmenopausal women.
A biomarker for both ALS and FTD, 2 neurological disorders that share clinical, genetic, and pathological traits, can help signal disease onset and the progression of degeneration.